Back to search

Article

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

2020-05-26

Abstract excerpt

<title>Abstract</title> <p><bold>Background.</bold> The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (<65, 65–74, and ≥75 years) are uncertain. We examined retention rates reflecting the effectiveness and safety of bDMARDs in actual clinical practice for clarifying optimal therapeutic strategies for rheumatoid arthritis (RA) by age groups.<bold>Methods.</bold...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
67451902-7ac1-5dd3-9fcb-962d49098920
DOI
10.21203/rs.2.23604/v3
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registryDOI 10.21203/rs.2.23604/v3
Unincreased mortality of patients with early rheumatoid arthritis compared to the general population in the past two decades: results from a Japanese prospective observational cohort: IORRASemantic proximity
Biologic retention rate and efficacy in patients with cluster-based phenotypes of ankylosing spondylitis: data from a Korean national biologics registry.Semantic proximity
Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss Clinical Quality Management cohortSemantic proximity
Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databasesSemantic proximity
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesSemantic proximity
Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic ManagementSemantic proximity
The Aftermath of Tapering Tocilizumab After Achieving Treatment Target In Patients With Rheumatoid Arthritis: A Nationwide Cohort StudySemantic proximity
Effectiveness and Safety of Intravenous Golimumab With and Without Concomitant Methotrexate in Patients With Rheumatoid Arthritis in the Prospective, Noninterventional AWARE StudySemantic proximity
Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral StrategySemantic proximity
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?Semantic proximity
Add-on Iguratimod or Tacrolimus in Methotrexate Inadequate Rheumatoid Arthritis: Efficacy, Safety and Propensity Score-Matched AnalysisSemantic proximity
Select a neighboring publication to make it the new centre.